Oxford Nanopore Technologies has raised £109.5m through a combination of £29.3m in new capital and the sale of £80.2m in secondary shares. This brings the total primary investment in the firm, to date, to £480m.
Last year, Oxford Nanopore Technologies’ highlights ranged from scaling up to population-scale sequencing with PromethION, to accurate, rapid testing in cancer and infectious disease.
The company also opened its first production facility in July. The building is designed to look like the firm’s MinION portable device for DNA and RNA sequencing.
Oxford biotech company e-therapeutics is offering its powerful network-biology-and AI-based drug discovery platform to help tackle the Covid-19 pandemic.
Using its proprietary tech, a biotech company has discovered antibodies leading to the development of drug discovery programmes in kidney disease and cancer.
Researchers in Oxford and Zurich have used artificial intelligence (AI) and computer visualisation technology to detect changes in colon cancer cells that could be connected to the ‘expression’ of some smell-sensing genes.